COMPASS Pathways plc

COMPASS Pathways plc is a biotechnology company focused on mental health, operating in the United Kingdom and the United States. Its primary product is COMP360, a psilocybin therapy currently in Phase III clinical trials for treatment-resistant depression. The company is also investigating COMP360 in Phase II trials for post-traumatic stress disorder (PTSD) and anorexia nervosa. COMPASS Pathways aims to address unmet needs in mental health care through innovative therapies. The company was formerly known as COMPASS Rx Limited before rebranding in August 2020.

COMPASS Pathways plc is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol CMPS. Its shares trade in US Dollars (USD), reflecting its primary listing on a US exchange. The company is headquartered in London, United Kingdom, but its stock is accessible to international investors through the Nasdaq. The choice of a US listing provides exposure to a broad investor base and aligns with its operations in the United States.

COMPASS Pathways plc operates in the Healthcare sector, specifically within the Medical Care Facilities industry. This classification reflects its focus on developing therapies for mental health conditions, which are delivered through clinical settings. As a biotechnology company, it conducts research and clinical trials to bring new treatments to market. The Medical Care Facilities industry encompasses entities that provide medical services, and COMPASS Pathways' work with psilocybin therapy fits within this framework as it aims to offer novel care options for patients with mental health disorders.

COMPASS Pathways plc is headquartered in London, United Kingdom, and was incorporated in 2020. The company serves markets in the United Kingdom and the United States, focusing on mental health treatment. Its clinical trials for COMP360 are conducted in these regions, targeting conditions like treatment-resistant depression, PTSD, and anorexia nervosa. The company's operations span both countries, leveraging expertise from the UK and US healthcare systems. Despite being UK-based, its Nasdaq listing and US-focused trials highlight a significant presence in the American market.

COMP360 is a proprietary psilocybin therapy developed by COMPASS Pathways plc. It is currently in Phase III clinical trials for treatment-resistant depression, a condition where patients do not respond to standard antidepressants. Additionally, COMP360 is being studied in Phase II trials for post-traumatic stress disorder (PTSD) and anorexia nervosa. Psilocybin is a psychedelic compound that, when administered in a controlled setting, may help reset neural pathways. COMPASS Pathways is pioneering this approach to address serious mental health conditions with limited treatment options, aiming to provide new hope for patients.